GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx (Nasdaq: WGS) announced significant findings from the SeqFirst study, conducted with Seattle Children's, demonstrating the effectiveness of rapid genomic testing in non-critical pediatric inpatients. The study revealed that implementing rapid exome sequencing (rES) and rapid genome sequencing (rGS) as first-tier tests dramatically reduced diagnosis time from 289 days to just 13 days.

The research showed a high diagnostic yield exceeding 40%, comparable to critical care settings. Key findings include a 91% rate of genetic testing recommendations from providers and a threefold increase in precise genetic diagnoses from initial encounters when using rES/rGS as first-line testing.

GeneDx (WGS) announces a significant development as the American Academy of Pediatrics (AAP) now recommends exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability. This updated guidance represents a major shift from the 2014 recommendations, which favored narrower testing methods. The change is expected to reduce the typical five-year diagnostic odyssey and improve patient outcomes through earlier interventions. GeneDx, having sequenced over 800,000 exomes and genomes, positions itself as a leader in this space with results available in as little as three weeks. The company emphasizes that this new approach will empower general pediatricians to take a more active role in genetic medicine, supported by expanding insurance coverage across the country.

Galatea Bio and Fabric Genomics have announced a strategic partnership to enhance genetic testing by combining rare pathogenic variant analysis with polygenic risk scoring (PRS) for common diseases. The collaboration will initially focus on cardiovascular gene panels based on AHA recommendations, with PRS for conditions like coronary arterial disease, cholesterol issues, and diabetes. Future expansion includes hereditary cancer panels with PRS for breast, colorectal, and prostate cancers. The partnership integrates Fabric Genomics' clinical reporting platform with Galatea Bio's StrataRisk™ PRS solution, which provides ancestry-adjusted genetic risk assessment using data from the Galatea Bio Global Biobank. The combined approach aims to deliver more comprehensive and accurate risk profiles across diverse populations through the Broad Clinical Lab's Blended Genome - Exome platform.

GeneDx (WGS), a genomic insights company, announced its participation in two upcoming investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference in New York City on June 4 at 9:55 a.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach on June 9 at 4:00 p.m. ET.

Both presentations will be available via live and archived webcasts on the company's investor relations website. GeneDx specializes in rare disease diagnostics through exome and genome testing, focusing on delivering personalized healthcare solutions and advancing drug discovery.

GeneDx (WGS) has published an article in the American Journal of Medical Genetics highlighting its vision for implementing AI in genomic diagnostics. The company aims to leverage its comprehensive genomic and phenotypic dataset to enhance genetic disease diagnosis through AI applications. The publication demonstrates GeneDx's strategy to address the growing demand for genetic testing as costs decrease and testing becomes standard care.

Key developments include AI systems for extracting phenotypic data and prioritizing genetic variants, working alongside genetics professionals. Following the recent acquisition of Fabric Genomics, GeneDx is positioning itself to enable decentralized testing with centralized intelligence, potentially setting new standards in genomic medicine globally.

GeneDx (WGS) has completed its acquisition of Fabric Genomics, a leader in AI-powered genomic interpretation. The strategic combination creates an integrated ecosystem for genomic diagnostics, offering both centralized and decentralized testing solutions powered by GeneDx's clinical expertise and Fabric's AI technology. Fabric Genomics will operate as an independent subsidiary of GeneDx.

The acquisition accelerates key growth opportunities including: faster diagnosis for critically ill newborns through NICU genomic testing, support for global newborn screening programs, international commercial expansion across EMEA, APAC, and LATAM regions, and new recurring revenue streams through Fabric's interpretation-as-a-service model.

GeneDx reported strong Q1 2025 financial results, with total revenues reaching $87.1 million, marking a 42% year-over-year increase. The company's core exome and genome test revenue grew impressively by 62% to $71.4 million, with test volume up 24% to 20,562 tests.

Key highlights include achieving an adjusted gross margin of 69% and adjusted net income of $7.7 million, compared to a loss in Q1 2024. The company announced plans to acquire Fabric Genomics and launched new initiatives including ultraRapid Whole Genome Sequencing and Epic Aura integration.

GeneDx raised its 2025 revenue guidance to $360-375 million and maintains its target of at least 30% growth in exome/genome volume and revenue. The company expanded its coverage to 33 states for pediatric outpatient testing and 14 states for NICU rapid genome sequencing, positioning itself for continued growth in genomic medicine.

GeneDx (WGS) has announced plans to acquire Fabric Genomics, an AI-powered genomic interpretation pioneer, in a deal worth up to $51 million. The acquisition combines GeneDx's extensive rare disease data asset with Fabric Genomics' AI platform to enable decentralized testing with centralized intelligence.

The transaction, expected to close in Q2 2025, includes $33 million in cash upon closing, with additional $18 million tied to milestone achievements. This strategic move will expand GeneDx's addressable market through multiple revenue streams:

• NICU Genomic Testing: Targeting the underserved market where less than 5% of 400,000 annual NICU admissions receive genetic testing
• Genomic Newborn Screening: Addressing a market of 3.7M U.S. births and 130M globally
• Global Commercial Expansion: Enabling local sequencing with centralized AI interpretation
• Platform Economics: Leveraging 750,000+ exomes/genomes dataset for AI development and clinical decision support

GeneDx (Nasdaq: WGS), a genomic insights company, has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company's management will hold a conference call at 8:30 a.m. Eastern Time on the same day to discuss the quarterly financial and operating results. Interested investors must register online to participate in the conference call. Both live and archived versions of the event will be accessible through the 'Events' section on GeneDx's investor relations website.